Pharmacovigilance re-established in Syria

Around the world / 10 May 2019

Photo: Shutterstock (edited)

Despite seven years of crisis, a dedicated team of health professionals have put Syria on the world pharmacovigilance map.

In early 2011, a national pharmaco­vigilance unit was established as a small department in the Syrian ministry of health. By the end of that year, the unit was linked to public hospitals, national health programmes, and local pharma­ceutical manufacturers. With these elements in place, Syria was admitted as an associate member of the WHO Programme for International Drug Monitoring in June 2012. 

The unit made a solid start. It created an official online adverse drug reaction reporting form, initiated training programmes, assigned pharmacovigilance officers in government hospitals, and mandated all pharmaceutical companies working in Syria to commission pharmacovigilance officers.

But, as the Syrian crisis escalated, sanctions deprived the country of many medicines, forcing the country to seek alternatives. Many major local pharmaceutical manufacturers were out of service due to increased violence in the north, which hampered medicines accessibility in the country.

Accordingly, health authorities’ priorities shifted towards providing access to basic medicines and health services. Unfortun-ately, this came at the expense of the national pharmacovigilance programme. Many of the local pharmacovigilance staff were moved to other departments and the national programme was rendered non-functional.

But while many staff assumed other roles in the ministry, they kept their commitment to promoting the goals and importance of the programme to decision makers in the country. In early 2017, the unit was reinstated in the ministry of health, bringing back some of the original staff.

“Three professional staff work now at the Pharmacovigilance Unit, one pharmacist with a PhD in clinical pharmacy, one physician with an MSc in pharmacology, and one pharmacy technician,” said the unit’s head, Linda Hsien.

With a team back in place, the unit has now overcome compatibility issues between the national and international reporting formats. 

“The Pharmacovigilance Unit uses VigiFlow to build the national database and to submit reports to the WHO database,” said Dr Hsien.

In October 2018, Syria’s pharmacovigilance unit became the 133rd member of the WHO Programme for International Drug Monitoring. Dr Hsien explained that the unit now has a network of representatives in the majority of the country’s public hospitals, provides lectures and training courses on pharmacovigilance principles and ADR reporting, and receives ADR reports from both healthcare professionals and patients.

Many challenges still await: awareness of the programme and participation by different stakeholders remains limited, training is needed to increase human resources, and tools and technologies still need to be developed to encourage reporting and active participation. Nevertheless, despite years of hardship, instability, and conflict, committed Syrian professionals have achieved international recognition for their national pharmacovigilance programme.


Read more:

Anas Bahnassi
College of Pharmacy, Taibah University, Saudi Arabia; College of Pharmacy, Al-Rasheed University, Syria

You may also like

Building a patient safety culture in India

India is one of the biggest pharmaceutical markets in the world. Read about the key stakeholders and initiatives driving medicine safety in this dynamic and complex country.

Around the world / 24 September 2021

Paraguay deploys technology to promote ADR reporting

Smart solutions and an integrated approach across both public and private sectors are helping Paraguay build a dynamic reporting culture and practice.

Around the world / 08 September 2021

Egypt addresses safety issues faced by refugee community

A universal problem for refugees is the loss of vital health records. ISoP Egypt Chapter is working to reduce medication errors and improve reporting for this vulnerable community.

Around the world / 22 October 2021

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean that we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies.

Find out more